Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Tempus Announces $200 Million Series G-2 Financing

Tempus, a leader in artificial intelligence and precision medicine, announced an additional $200 million financing at a post-money valuation of $8.1 billion dollars, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price. With these investments, Tempus has now raised around $1.05 billion.

Recommended AI News: AirTrunk Unveils Singapore’s Largest Independent And Most Efficient Hyperscale Data Centre

The company is using the additional funds to expand its operations and establish its work in other disease areas, including infectious diseases, depression, and cardiology. Tempus now employs approximately 1,500 people and runs millions of molecular tests annually. In addition, Tempus has been able to aggregate one of the largest repositories of healthcare data in the world, which it uses to help personalize care and ensure that every patient is on their own optimal, therapeutic path.

Related Posts
1 of 14,052

“Never before has the need to bring the power and promise of technology to healthcare been more acute than it is today,” said Eric Lefkofsky, Founder and CEO at Tempus. “As a leader in this space, we are very much aware of our responsibility and the power of this moment in time; one in which we now possess the technological capability to use artificial intelligence to eradicate disease and help people live longer and healthier lives.”

Recommended AI News: RAKBANK Chooses Anomali Threat Intelligence Product Suite To Detect Threats Across Its Banking Infrastructure

Tempus is focused on advancing precision medicine through its proprietary data platform that ingests multi-modal data across major disease types and analyzes that data looking for therapeutically relevant insights. Tempus organizes phenotypic, morphological, and molecular data in real-time, enabling the company to add clinical context to physician-ordered laboratory tests. Tempus’ “smart” laboratory tests are available clinically, touching the lives of millions of patients in the U.S.

Recommended AI News: WiSeKey Signs A $15.5 Million High Growth Capital Investment Agreement With Alpha Blue Ocean To Finance The Acquisition Of Arago And Integration Of Artificial Intelligence On Its Cybersecurity Platform

Leave A Reply

Your email address will not be published.